surmount-1 tirzepatide non-diabetic weight loss trial Tirzepatide for Obesity: Highlights from the SURMOUNT-1 Efficacy and Safety of Tirzepatide

Our tirzepatide niacinamide guide covers this combination thoroughly

SURMOUNT-OSA results [1] After one year, 42% of adults on Zepbound and 50% of adults on Zepbound with PAP therapy experienced remission or mild, non-symptomatic OSA, compared to 16% and 14% on placebo, respectively

The median follow-up time to diagnosis after treatment initiation was 3.7 years

Check your refrigerator thermometer regularly to confirm it maintains the correct temperature range, as older units may drift and compromise medication stability

Coordinate ordering with your BUD Many people order their next vial immediately after finishing the current one

No compounded medication carries the same safety assurance as an FDA-approved product